Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Join SI Premium – FREE
Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.75), $0.03 worse than the analyst estimate of ($1.72).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
- Redburn starts Mettler-Toledo at Sell, sees valuation outpacing growth
- Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
